Vimseltinib - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Vimseltinib

Brand Name:

Romvimza

Strength:

14mg, 20mg, 30mg

HCPCS:

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Tyrosine Kinase Inhibitor

Minor Drug Class:

CSF1R

Oral (Y/N):

Yes

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use